The stock of Ocular Therapeutix Inc (OCUL) has seen a -4.03% decrease in the past week, with a 9.16% gain in the past month, and a -13.06% decrease in the past quarter. The volatility ratio for the week is 4.92%, and the volatility levels for the past 30 days are at 7.47% for OCUL. The simple moving average for the past 20 days is -1.01% for OCUL’s stock, with a -11.89% simple moving average for the past 200 days.
Is It Worth Investing in Ocular Therapeutix Inc (NASDAQ: OCUL) Right Now?
Moreover, the 36-month beta value for OCUL is 1.51. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 6 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for OCUL is 133.91M and currently, short sellers hold a 9.58% of that float. On March 26, 2025, OCUL’s average trading volume was 1.20M shares.
OCUL) stock’s latest price update
Ocular Therapeutix Inc (NASDAQ: OCUL)’s stock price has plunge by -1.86relation to previous closing price of 7.53. Nevertheless, the company has seen a -4.03% plunge in its stock price over the last five trading sessions. fool.com reported 2025-03-14 that The market was seeing Ocular Therapeutix (OCUL -6.52%) very positively this week, and that sunny view pushed the company’s stock higher.
Analysts’ Opinion of OCUL
Many brokerage firms have already submitted their reports for OCUL stocks, with RBC Capital Mkts repeating the rating for OCUL by listing it as a “Outperform.” The predicted price for OCUL in the upcoming period, according to RBC Capital Mkts is $17 based on the research report published on March 18, 2025 of the current year 2025.
Needham, on the other hand, stated in their research note that they expect to see OCUL reach a price target of $15. The rating they have provided for OCUL stocks is “Buy” according to the report published on March 11th, 2025.
OCUL Trading at -2.12% from the 50-Day Moving Average
After a stumble in the market that brought OCUL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.24% of loss for the given period.
Volatility was left at 7.47%, however, over the last 30 days, the volatility rate increased by 4.92%, as shares surge +7.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.31% lower at present.
During the last 5 trading sessions, OCUL fell by -3.31%, which changed the moving average for the period of 200-days by +43.17% in comparison to the 20-day moving average, which settled at $7.47. In addition, Ocular Therapeutix Inc saw -13.47% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OCUL starting from Dugel Pravin, who sale 21,475 shares at the price of $6.87 back on Feb 24 ’25. After this action, Dugel Pravin now owns 3,520,318 shares of Ocular Therapeutix Inc, valued at $147,533 using the latest closing price.
Heier Jeffrey S., the Chief Scientific Officer of Ocular Therapeutix Inc, sale 3,061 shares at $6.87 during a trade that took place back on Feb 24 ’25, which means that Heier Jeffrey S. is holding 265,998 shares at $21,029 based on the most recent closing price.
Stock Fundamentals for OCUL
Current profitability levels for the company are sitting at:
- -2.7 for the present operating margin
- 0.91 for the gross margin
The net margin for Ocular Therapeutix Inc stands at -3.04. The total capital return value is set at -0.41. Equity return is now at value -95.21, with -54.51 for asset returns.
Based on Ocular Therapeutix Inc (OCUL), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -1.78. The debt to equity ratio resting at 0.24. The interest coverage ratio of the stock is -12.65.
Currently, EBITDA for the company is -176.14 million with net debt to EBITDA at 1.8. When we switch over and look at the enterprise to sales, we see a ratio of 13.47. The receivables turnover for the company is 1.97for trailing twelve months and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.66.
Conclusion
To wrap up, the performance of Ocular Therapeutix Inc (OCUL) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
